ArticleInternational journal of chronic obstructive pulmonary disease
Ultrafine particles in airways: a novel marker of COPD exacerbation risk and inflammatory status.
Article in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Biomarkers of the relationship of particulate matter exposure with the progression of chronic respiratory diseases.The Korean journal of internal medicine · 2024Pooled it
- Indoor particulate matter concentrations and air cleaner intervention association with biomarkers in former smokers with COPD.Environmental research · 2024Trial
- Impact of smoking on redox homeostasis and 8-OHdG levels in COPD patients: a cross-sectional comparative study.BMC pulmonary medicine · 2025Article
- Implications of DNA damage in chronic lung disease.Frontiers in cell and developmental biology · 2024Review
- Serum lactate dehydrogenase is associated with impaired lung function: NHANES 2011-2012.PloS one · 2023Article
- COVID-19 Lockdown in Israel: The Environmental Effect on Ultrafine Particle Content in the Airway.International journal of environmental research and public health · 2022Observational
- Challenges in Quantifying 8-OHdG and 8-Isoprostane in Exhaled Breath Condensate.Antioxidants (Basel, Switzerland) · 2022Article
- Article
- Trajectory of inhaled cadmium ultrafine particles in smokers.BMJ open respiratory research · 2021Article
- Cigarette-related cadmium and environmental pollution exposure are reflected in airway ultrafine particle content.ERJ open research · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeUltrafine particles (UFP) are toxic due to their small size and penetration into deeper lung compartments. We aimed to evaluate the exhaled breath condensate (EBC)-UFP content as a reflection of inflammation and oxidative stress status in COPD patients and as an exacerbation risk marker.
methodsEBC was collected by conventional methods. Particles were analyzed with NanoSight LM20. EBC carbonyl and 8-hydroxydeoxyguanosine (8-OHdG) levels were measured using ELISA kits. Study population (58 COPD patients and 40 healthy smoker and non-smoker controls) underwent spirometry, diffusion capacity, EBC testing, and blood sampling.
resultsAbsolute eosinophil count, C-reactive protein (CRP), and lactate dehydrogenase in serum were elevated in the COPD group compared with the controls (224 U/L, 5 mg/L, and 391 U/L vs 154 U/L, 3 mg/L, and 330 U/L,
conclusionUFP content in EBC reflects the inflammatory state of airways. Low UFP concentrations in EBC and high in serum of COPD patients support our hypothesis that increased epithelial permeability could be the mechanism behind those findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.